A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

When Trova Wine and Market shut its doors last month after nearly five years in business in Dallas, owner Michelle Bonds pointed to an unexpected reason for closure: GLP-1 weight loss drugs like ...

Diabetes, a condition where blood glucose levels cannot be controlled, affects more than 10% of the adult population worldwide, and more than 90% of those have type 2 diabetes. Although the ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.

"The MC4R pathway plays a key role in eating behavior ... obesity as a stand-alone treatment or in conjunction with GLP-1/GIP therapy. Additional trial information can be found at https ...